Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.

ABSTRACT:

Objective

To systematically review the literature regarding safety of disease-modifying drug (DMD) use during pregnancy on perinatal and developmental outcomes in offspring of patients with multiple sclerosis (MS).

Methods

A PubMed and EMBASE search up to February 2012 was conducted with a manual search of references from relevant articles. Selected studies were evaluated using internationally accepted criteria.

Results

Fifteen studies identified 761 interferon β-, 97 glatiramer acetate-, and 35 natalizumab-exposed pregnancies. Study quality ranged from poor to good; no study was rated excellent. Small sample sizes limited most studies. Compared with data for unexposed pregnancies, fair- to good-quality prospective cohort studies reported that interferon β exposure wa

SUBMITTER: Lu E 

PROVIDER: S-EPMC3525300 | biostudies-literature | 2012 Sep

REPOSITORIES: biostudies-literature